New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
04:55 EDTCGIX, CGIX, CGIX, HART, HART, HART, NURO, NURO, NURO, CANF, CANF, CANF, AMBS, AMBS, AMBS, AGEN, AGEN, AGEN, AVXL, AVXL, AVXL, SYN, SYN, SYN, CEMI, CEMI, CEMI, SRNE, SRNE, SRNE, OXBT, OXBT, OXBTOneMedPlace to hold a forum
7th Annual OneMedForum SF 2014 is being held in San Francisco on January 13-15.
News For CGIX;SRNE;CEMI;SYN;AVXL;AGEN;AMBS;CANF;NURO;HART;OXBT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
07:10 EDTAGENMaidStone Life Sciences to hold a conference
Subscribe for More Information
March 24, 2015
07:26 EDTSRNECelgene drug competitor will need additional studies, says UBS
Subscribe for More Information
March 23, 2015
07:05 EDTCANFCan-Fite signs distribution agreement for CF101 with Cipher Pharmaceuticals
Can-Fite BioPharma (CANF) announced it has signed a distribution agreement with Cipher Pharmaceuticals (CPHR) to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals. Under the terms of the distribution agreement, Cipher is making an upfront payment of C$1.65M to Can-Fite. In addition, the agreement provides that additional payments of up to C$2M will be received by Can-Fite upon the achievement of certain milestones plus royalty payments of 16.5% of net sales of CF101 in Canada. The agreement further provides that Can-Fite will deliver finished product to Cipher. The timeline to regulatory submissions to Health Canada will be determined by the completion of the remaining clinical trial program. to Global Data, the psoriasis treatment market was worth $3.6 billion in 2010 and is forecast to grow to $6.7B by 2018. According to independent business information provider visiongain, the global rheumatoid arthritis drug market is expected to generate revenues of $38.5B in 2017.
March 22, 2015
11:13 EDTSYNSynthetic Biologics has lunch meeting with Philadelphia Securities Association
Subscribe for More Information
March 19, 2015
09:20 EDTSYNOn The Fly: Pre-market Movers
Subscribe for More Information
08:14 EDTHARTHarvard Apparatus sees capital lasting until mid-2016
Subscribe for More Information
08:08 EDTHARTHarvard Apparatus reports Q4 EPS (36c), one estimate (27c)
Subscribe for More Information
06:58 EDTSYNSynthetic Biologics announces positive PK results from SYN-004 trials
Subscribe for More Information
March 18, 2015
07:03 EDTCANFCan-Fite BioPharma completes development of commercial biomarker test
Subscribe for More Information
March 16, 2015
14:03 EDTSYNSynthetic Biologics downgraded to Hold from Buy at Maxim
Maxim downgraded Synthetic Biologics to Hold following management's decision no to move SYN-005 for pertussis until funding is found, which creates another uncertainty regarding the timeline. Price target is $3.
09:05 EDTSRNENantWorks and Sorrento announce global collaboration to develop immunotherapies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use